Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia

Abstract: A therapeutic agent for the treatment of xerostomia comprises a derivative of spirooxathiolane-quinuclidine or an acid addition salt thereof as an active ingredient represented by the following formula [I]: (wherein R¹ and R² may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol, or alkyl which may be substituted by one or more aryl groups). The above therapeutic agent can be administered orally or parentally and cure xerostomia. Specifically, the agent can be used for improving and/or curing dry mouth caused by various diseases with organic changes in salivary gland, lesions in salivary gland accompanied with systemic diseases, necrosis of salivary gland cell by radiotherapy, HIV infection (AIDS), hypo-function of saliva secretion, affection of various medicines taken and, further, mental fatigue or bad conditions due to complex social life situations.

Description: The present invention relates to the use of a derivative of spirooxathiolane-quinuclidine or an acid addition salt thereof for the manufacture of a medicament for the treatment of non - Sjögren - syndrome xerostamia. Stomatoxerosis is generally called "xerostomia" or "dry mouth" and its manifestation is characterized by decreased or deficient secretion of saliva caused by various factors. Since extremely many factors are related to the secretion of saliva, it is very difficult to investigate the cause of xerostomia. Considering the causes, it is known that various diseases with organic changes in salivary gland, lesion in salivary gland accompanied with systemic diseases, necrosis of salivary gland cell caused by radiotherapy, HIV infection, hypofunction of secretion caused by aging, affection by various medicines taken and, further, mental fatigue or bad conditions due to complex social life situations bring about these symptoms. In the aged, stomatoxerosis is a common symptom, which are observed in 16% of the male of the age older than 70 years and 25% of the female of the same age as above and are considered to be a regressive change in salivary gland by aging. Further,there are many pharmaceutical drugs causing hyposecretion of salivary gland, eg., some paper reported that the number of such drugs is more than 100, and another paper reported that the ratio of the patients complaining dry mouth increased as the number of the species of drugs administered increased. For example, diuretics such as trichloromethiazide, furosemide, etc., antihypertensive such as reserpine, clonidine hydrochloride, etc., anticholines such as atropine sulfate, etc., antihistamines such as chlorpheniramine maleate, etc., various types of antitussives and expectorants, antiparkinsonism agents, psychotropic agents, antidepressants, tranquilizers, muscle relaxants, etc., are exemplified as drugs causing dry mouth. In addition, while radiotherapy has been playing an important role for the treatment of malignant tumor in the field of stomatosurgery and otolaryngology, severe injury in salivary gland is inevitable due to a broad radiation area on the treatment, leading to severe xerostomia. The number of such patients as the above is anticipated to increase with the prevalence of radiotherapy. Symptoms of xerostomia are not only sensing intraoral dryness but also causing extremely many and severe problems in daily life such as intraoral utrication, pain, glossalgia, dysgeusia, atrophy of papilla lingualis, inflammation of tunica mucosa oris, ulceration, rhagades of lingua orangulus oris, dificulties in mastication, somatic swallow or conversation and so on. Therefore, an appropriate countermeasure to the above is strongly required. At present the methods of treatment of these symptoms include artificial saliva, mouth-washer, etc., but these have only a temporary wetting effect in mouth. Alternately, parotin, cepharanthin and various kinds of chinese medicines are used in practice, but unfavarable adverse effect or insufficient therapeutic effect of the above have been observed. Thus, the therapeutic methods for xerostomia have not yet established. The present invention aims to synthesize chemical compounds to augment saliva secretion by stimulating exocrine glands, particularly, muscarinic M 3 receptor and to provide a therapeutic agent for the treatment of xerostomia without systemic adverse effect and with least toxicity to alleviate pain of the patients with dry mouth, based on the recent developement of the research on parasympathetic nerve system, that is, cholinergic receptor. The present inventors have synthesized,various compounds and investigated their efficacy to attain the above aim and found that a certain kind of derivative of spirooxathiolane-quinuclidine or an acid addition-salt thereof having a formula [I] exhibits an excellent effect and accomplished the present invention. Accordingly, the present invention relates to the use of a derivative of spirooxathiolane-quinuclidine or an acid addition salt thereof having a formula [I] as an active ingredient (wherein R 1 and R 2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol or alkyl which is substituted by one or more aryl groups) in the manufacture of a medicament for the treatment of non-sjögren-syndrome xerostomia. EP 0578511 discloses the use of such compounds in the manufacture of a medicament for the treatment of Sjögren-syndrome. Gen.Pharmac. vol 25 No. 1, pp 123-129, 1994 notes the sialogogic effects of cis-2-methylspiro (1,3-oxathiolane - 5,3') quinuclidine hydrochloride hemihydrate and suggests the use of this compound in the the treatment of xerostomia in patients with Sjögren-syndrome. Alkyl group of the compounds represented in the aforementioned formula [I] can be methyl, ethyl, n-propyl, iso-propyl, butyl, sec-buyl, tert-butyl, etc., and aryl group can be phenyl and so on. These compounds are described in Japanese patent laid-open (kokai) No. 280,497/1986 and are known in the art. The following compounds among these can be exemplified as derivatives of spirooxathiolane-quinuclidine used in the present invention: 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine 2-diphenylmethylspiro(1,3-oxathiolane-5,3')quinuclidine 2-methyl-2-phenylspiro(1,3-oxathiolane-5,3')quinuclidine These compounds include geometrical isomers, enantiomers, diastereomers, racemates and any of these. In addition, acid addition salts thereof include either inorganic or organic acid addition salts, such as those of hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, lactic acid, succinic acid, maleic acid and so on. Further, the derivatives of spirooxathiolane-quinuclidine can be easily prepared by the methods described in the aforementioned Japanese patent laid-open (kokai) No. 280,497/1986, for example, by reacting 3-hydroxy-3-mercapto-methyl-quinuclidine with a carbonyl compound represented in a formula R 1 -CO-R 2 (R 1 -and-R 2 can be the same as the above), followed by isolation of the objective compound from the reaction mixture. Isolation of an optical isomer or other isomer from these compounds can be carried out by the method described in the above laid-open patent or in Japanese patent laid-open (kokai) No. 22,280/1990. Among the derivatives used in the present invention, 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride represented in the following formula [II], especialy, cis-isomer, or a mixture of cis-isomer and trans-isomer enriched with the cis-isomer is preferred because of its higher therapeutic effect. When the therapeutic agent for the treatment of xerostomia of the present invention is applied for curing disease, the compound represented in the aforementioned formula [I] is administered as an active ingredient singly, or being combined with pharmaceutically acceptable carriers in a suitable dosage form of pharmaceutical composition for oral, parenteral, topical or rectal administration, eg., capsules, tablets, powders, granules, injections, ointments, suppositories and so on. As pharmaceutical preparations suitable for oral administration, solid compositions such as cap sules , tablets, powders, granules, or troches; and liquid compositions, such as syrups or suspensions, are exemplified. These compositions for oral administration such as capsules, tablets and granules are prepared according to a usual method in the art, using vehicles, for example, starch, lactose, white sugar, mannitol, carboxymethylcellulose, corn starch, inorganic salts and so on. In addition to these vehicles, binders, disintegrators, surfactants, lubricants, fluidity accelerators, correctives, colorants, perfumes etc., may be used appropriately. Specific examples are described as follows: [Binders] Starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone and Macrogol (trade mark); [Disintegrators] Starch, hydroxypropyl starch, sodium carboxymethylcellulose, cross-linked sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose and low-substituted hydroxypropylcellulose; [Surfactants] Sodium lauryl sulfate, soybean lecithin, sucrose fatty acid esters and Polysorbate 80 (trademark); [Lubricants] Talc, waxes, hydrogenated vegetable oils, sucrose fatty acid esters, magnesium stearate, calcium stearate, aluminum stearate and polyethylene glycol; [Fluidity accelerators] Light silicic acid anhydride, dry aluminum hydroxide gel, synthetic aluminum silicate and magnesium silicate; The compounds represented in a generic formula [I] may be administered in a dosage form of suspension,emulsion, syrup, elixir, etc., which may contain a corrective and/or a colorant. It is desirable that these compositions contain 1-95 wt% of an active ingredient. Injections are exemplified as pharmaceutical preparation suitable for parenteral administration. These parenteral formulations may be prepared according to a usual method in the art and, generally, distilled water for injection, physiological saline, an aqueous glucose solution, vegetable oils for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, polyethylene glycol, etc., can be used as a diluent. In addition, a germicide, a preservative and a stabilizer may be added, if necessary. Considering the stability of compositions for parenteral administration, they may be filled in vials or the like, freezed and lyophylized by a usual method in the art so as for water therein to be removed, followed by repreparation of solutions from lyophylized compositions just before their use. In addition, if necessary, isotonic agents, stabilizers, preservatives, soothing agents, etc., may be added appropriately. An injection preparation, for example, as a salt form, may be dissolved in usual water for injection or may be prepared in a dosage form suitable for injection such as a suspension or an emulsion in the mixture of pharmaceutically acceptable oil or liquid. In these cases, germicides such as benzylalcohol, anti-oxidants such as ascorbic acid, buffers, osmotic pressure modifiers, solution ajuvants, etc., may be added. It is preferable the injection preparation to contain 0.1-5wt.% of an active ingredient. This can be used in a dosage form of intravenous, intraarterial, intramuscular or subcutaneous injection. As a pharmaceutical preparation suitable for topical or rectal administration, ointments and suppositories are exemplified. According to a conventional method, ointments can be prepared by adding basic vehicles used usually and preferably contains 0.5-30wt.% of an active ingredient. Suppositories may comprise pharmaceutical carriers known in the art, such as polyethylene glycol, lanolin, cacao fat, fatty acid triglyceride and prefarably contains 1-95wt.% of an active ingredient. The above pharmaceutical preparations suitable for oral, parenteral, topical or rectal application may be prepared, according to the methodsknown in the art, in order to release an active component to release rapidly, slowly or retardedly after the administration in a patient. The dose level of the therapeutic agent for the treatment of xerostomia varies with dosage form, administration method, purpose for application, and the age, the body weight and disease conditions of a patient and, generally, is prefarably in a range from 1mg to 1g per one adult. The agent is administered in one dose or divided into several portions. The content of an active ingredient in a pharmaceutical preparation is appropriately determined according to the above dose level. The therapeutic agents for the treatment of xerostomia are administered orally or parenterally, and a derivative of spirooxathiolane-quinuclidine as an active ingredient acts on exocrine glands, stimulates muscarinic M 3 receptor and augments secretion of saliva without adverse effects. Accordingly, the agents can be used for improving and/or curing dry mouth, specifically, caused by various diseases with organic changes in salivary gland, lesions in salivary gland complicated with systemic diseases, necrosis of salivary gland cell by radiotherapy, HIV infection, hypofunction of secretion caused by aging, affection of various medicines taken and further, mental fatigue or bad conditions due to complex social life situations and can be used for alleviating the pain in a patient. The present invention is further described more in detail in the following examples: [Example 1] A stimulative action on the secretion of saliva in old rats. A pharmacological activity test was carried out using 5 male Wister rats of the age 50 weeks old in one group. After rats were anesthetized by 40mg/kg of sodium pentobarbital, 0, 1, 5 and 25mg/kg of spirooxathiolane-quinuclidine derivative hydrochroride were administered intraveniously. Saliva secreted in mouth was collected on a cotton flower ball at 10, 30 and 60 minutes after the administration and the amount thereof was weighed. The results were shown in table 1. Animal group dose level No. of animals the amount of secreted saliva (mg/100g-body weight/minutes) (mg/kg) 10min. 30min. 60min. control group 0 5 0 1 0 administered group 1 5 3 3 1 administered group 5 5 7 5 3 administered group 25 5 12 9 5 As a result, administration of the aforementioned derivative of spirooxathiolane -quinuclidine hydrochloride increased the amount of saliva secretion in old rats. Accordingly, it was found that the above agent can prevent and/or cure dry mouth. [Example 2] A pharmacological activity test was carried out using 5 male Wister rats in one group. At first,1 mg of reserpine was orally administered. One hour later, 0, 5 and 25 mg/kg of a derivative of spirooxatiolane-quinuclidine hydrochloride represented in a formula [II] was orally administered. At 10, 30 and 60 minutes after the administration, saliva secreted in mouth was collected in a cotton flower ball and the amount thereof was weighed. Saliva secretion in the group treated with neither reserpine or quinuclidine derivative was observed in the same way as that in the other group. The results are shown in table 2. Animal group dose level No. of animals the amount of secreted saliva (mg/100g-body-weight/minutes) (mg/kg) 10min. 30min. 60min. non-treated group 0 5 1 2 2 control group 0 5 0 0 1 administered group 5 5 4 6 2 administered group 25 5 9 5 4 It became clear from the results that administration of the aforementioned of the spirooxa-thioquinuclidine derivative hydrochloride augmented saliva secretion in rats administered reserpine known to induce dry mouth as its adverse effect. [Example 3] Preparation example 1 Capsule Capsules of the following composition containing 100mg of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride were prepared according to a usual method in the art : 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride (formula II) 10g Low-substituted hydroxypropylcellulose(L-HPC) 20g Cross-linked carboxymethylcellulose sodium salt (Cross-linked CMC-Na) 5g Magnesium stearate 2g Lactose 63g 100g Preparation example 2 Tablets Tablets of the following composition containing 100 mg of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride were prepared according to a usual method in the art: 2-methylspiro (1,3-oxathiolane-5,3')quinuclidine hydrochloride (formula II) 20g Low-substituted hydroxypropylcellulose(L-HPC) 10g Crystalline cellulose 15g Hydroxypropylmethylcellulose(HPMC) 10g Magnesium stearate 1g Lactose q.s. 100g Preparation example 3 Injections Injections of the following composition containing 100 mg of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride according to a usual method in the art: 2-methylspiro(1,3-oxathio-5,3')quinuclidine hydrochloride (formula II) 1g Glucose 10g Distilled water for injection q.s 200 ml

Claims: Use of a derivative of spirooxathiolane-quinuclidine or acid addition salt thereof represented by the following formula [I] wherein R 1 and R 2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol or alkyl substituted by one or more aryl groups for the manufacture of a medicament for the treatment of non-Sjögren-syndrome xerostomia. Use according to claim 1 in which the derivative is 2-methylspiro(1,3-oxathiolane-5,3') -quinuclidine hydrochloride, represented by the following formula [II] Use according to claim 2 in which the 2-methylspiro(1,3-oxathiolane-5,3')-quinuclidine hydrochloride is the cis-isomer.

Inventors: HANDA HARUMI, TAKESHITA YASUYOSHI, HANDA, HARUMI, TAKESHITA, YASUYOSHI
Applicants: SNOW BRAND MILK PROD CO LTD, SNOW BRAND MILK PRODUCTS CO., LTD.
Application year: 1995
Main classification: A61K31
IPC codes: C07D497, A61P1, A61K31